- Patients with NSCLC and coexisting COPD who received palliative pembrolizumab had better OS, PFS, and objective response rates (ORR) than patients without COPD.
Why this matters
- Previous studies suggesting an association between coexisting COPD and longer PFS with immune checkpoint inhibitors in NSCLC used a clinical diagnosis of COPD or spirometry-defined COPD in
- 133 patients with lung cancer who received palliative pembrolizumab between July 2014 and January 2018 who had undergone spirometry testing for COPD within the past 3 years.
- Funding: Ministry of Trade, Industry, and Energy; others.
- 44% had COPD.
- Coexisting COPD was associated with better OS (aHR for death, 0.51; 95% CI, 0.28-0.90) and PFS (aHR for disease progression or death, 0.61; 95% CI, 0.37-0.99).
- ORR was higher in patients with vs without COPD (38.2% vs 20.5%; P=.028).
- Compared with patients with moderate or severe COPD, those with mild COPD had better OS (aHR for death, 0.27; 95% CI, 0.09-0.78) and PFS (aHR for disease progression or death, 0.21; 95% CI, 0.06-0.70).
- Retrospective, single-center study.